Diane V Havlir

Summary

Affiliation: University of California
Country: USA

Publications

  1. ncbi HIV integrase inhibitors--out of the pipeline and into the clinic
    Diane V Havlir
    N Engl J Med 359:416-8. 2008
  2. ncbi Effect of trimethoprim-sulphamethoxazole on the risk of malaria in HIV-infected Ugandan children living in an area of widespread antifolate resistance
    Anne F Gasasira
    School of Medicine, Makerere University Kampala, Uganda
    Malar J 9:177. 2010
  3. ncbi Placental malaria among HIV-infected and uninfected women receiving anti-folates in a high transmission area of Uganda
    Patrick M Newman
    School of Medicine, University of California, San Francisco, 513 Parnassus Ave, San Francisco, CA 94131, USA
    Malar J 8:254. 2009
  4. ncbi Confronting TB/HIV in the era of increasing anti-TB drug resistance
    Jeremiah Chakaya
    Centre for Respiratory Diseases Research, Kenya Medical Research Institute, Africa
    J Int AIDS Soc 11:6. 2008
  5. ncbi Productive infection maintains a dynamic steady state of residual viremia in human immunodeficiency virus type 1-infected persons treated with suppressive antiretroviral therapy for five years
    Diane V Havlir
    Department of Medicine, San Francisco General Hospital, University of California, San Francisco, California 94110, USA
    J Virol 77:11212-9. 2003
  6. ncbi Predictors of residual viremia in HIV-infected patients successfully treated with efavirenz and lamivudine plus either tenofovir or stavudine
    Diane V Havlir
    Department of Medicine, San Francisco General Hospital, University of California at San Francisco, San Francisco, California, USA
    J Infect Dis 191:1164-8. 2005
  7. ncbi Opportunities and challenges for HIV care in overlapping HIV and TB epidemics
    Diane V Havlir
    Department of Medicine, University of California, San Francisco, USA
    JAMA 300:423-30. 2008
  8. ncbi Timing of antiretroviral therapy for HIV-1 infection and tuberculosis
    Diane V Havlir
    University of California, San Francisco, 995 Potrero Ave, Bldg 80, Ward 84, San Francisco, CA 94110 2897, USA
    N Engl J Med 365:1482-91. 2011
  9. ncbi Mycobacterium tuberculosis microbiologic and clinical treatment outcomes in a randomized trial of immediate versus CD4(+)-initiated antiretroviral therapy in HIV-infected adults with a high CD4(+) cell count
    Gabriel Chamie
    Department of Medicine, University of California, San Francisco, CA, USA
    Clin Infect Dis 51:359-62. 2010
  10. ncbi Sex differences in HIV RNA level and CD4 cell percentage during childhood
    Theodore D Ruel
    Department of Pediatrics, University of California, San Francisco, California, USA
    Clin Infect Dis 53:592-9. 2011

Detail Information

Publications56

  1. ncbi HIV integrase inhibitors--out of the pipeline and into the clinic
    Diane V Havlir
    N Engl J Med 359:416-8. 2008
  2. ncbi Effect of trimethoprim-sulphamethoxazole on the risk of malaria in HIV-infected Ugandan children living in an area of widespread antifolate resistance
    Anne F Gasasira
    School of Medicine, Makerere University Kampala, Uganda
    Malar J 9:177. 2010
    ..This study assessed the incidence of falciparum malaria and the prevalence of resistance-conferring Plasmodium falciparum mutations in HIV-infected children receiving daily TS and HIV-uninfected children not taking TS...
  3. ncbi Placental malaria among HIV-infected and uninfected women receiving anti-folates in a high transmission area of Uganda
    Patrick M Newman
    School of Medicine, University of California, San Francisco, 513 Parnassus Ave, San Francisco, CA 94131, USA
    Malar J 8:254. 2009
    ..TS decreases the risk of malaria in HIV-infected adults and children but has not been evaluated among pregnant women...
  4. ncbi Confronting TB/HIV in the era of increasing anti-TB drug resistance
    Jeremiah Chakaya
    Centre for Respiratory Diseases Research, Kenya Medical Research Institute, Africa
    J Int AIDS Soc 11:6. 2008
    ..These interventions are best carried out by HIV control programmes which should therefore be encouraged to take greater responsibility in implementing these interventions...
  5. ncbi Productive infection maintains a dynamic steady state of residual viremia in human immunodeficiency virus type 1-infected persons treated with suppressive antiretroviral therapy for five years
    Diane V Havlir
    Department of Medicine, San Francisco General Hospital, University of California, San Francisco, California 94110, USA
    J Virol 77:11212-9. 2003
    ....
  6. ncbi Predictors of residual viremia in HIV-infected patients successfully treated with efavirenz and lamivudine plus either tenofovir or stavudine
    Diane V Havlir
    Department of Medicine, San Francisco General Hospital, University of California at San Francisco, San Francisco, California, USA
    J Infect Dis 191:1164-8. 2005
    ..05). However, a level of residual viremia <50 copies/mL was not associated with CD4 cell count changes or risk of virologic rebound through 72 weeks of follow-up...
  7. ncbi Opportunities and challenges for HIV care in overlapping HIV and TB epidemics
    Diane V Havlir
    Department of Medicine, University of California, San Francisco, USA
    JAMA 300:423-30. 2008
    ....
  8. ncbi Timing of antiretroviral therapy for HIV-1 infection and tuberculosis
    Diane V Havlir
    University of California, San Francisco, 995 Potrero Ave, Bldg 80, Ward 84, San Francisco, CA 94110 2897, USA
    N Engl J Med 365:1482-91. 2011
    ....
  9. ncbi Mycobacterium tuberculosis microbiologic and clinical treatment outcomes in a randomized trial of immediate versus CD4(+)-initiated antiretroviral therapy in HIV-infected adults with a high CD4(+) cell count
    Gabriel Chamie
    Department of Medicine, University of California, San Francisco, CA, USA
    Clin Infect Dis 51:359-62. 2010
    ..Trial registration. ClinicalTrials.gov identifier: NCT00078247 ...
  10. ncbi Sex differences in HIV RNA level and CD4 cell percentage during childhood
    Theodore D Ruel
    Department of Pediatrics, University of California, San Francisco, California, USA
    Clin Infect Dis 53:592-9. 2011
    ..Limited data exist regarding potential sex differences in HIV RNA level and CD4 parameters among prepubertal children with untreated HIV infection...
  11. ncbi Modification of the Abbott RealTime assay for detection of HIV-1 plasma RNA viral loads less than one copy per milliliter
    Steven A Yukl
    San Francisco VA Medical Center, San Francisco, CA 94121, USA
    J Virol Methods 175:261-5. 2011
    ..77 copy/ml; 95% CI 0.86-4.68 copy/ml). The measured viral load correlated inversely (r = -0.78; p = 0.028) with the total duration of viral suppression (viral load<40 copies/ml)...
  12. ncbi Neurocognitive and motor deficits in HIV-infected Ugandan children with high CD4 cell counts
    Theodore D Ruel
    Division of Infectious Disease, Department of Pediatrics, UCSF Benioff Children s Hospital, University of California, San Francisco, CA 94143 0136, USA
    Clin Infect Dis 54:1001-9. 2012
    ....
  13. ncbi Differences in HIV burden and immune activation within the gut of HIV-positive patients receiving suppressive antiretroviral therapy
    Steven A Yukl
    San Francisco Veterans Affairs Medical Center, San Francisco, California, USA
    J Infect Dis 202:1553-61. 2010
    ..The gut is a major reservoir for human immunodeficiency virus (HIV) in patients receiving antiretroviral therapy (ART). We hypothesized that distinct immune environments within the gut may support varying levels of HIV...
  14. ncbi Short-term risk of HIV disease progression and death in Ugandan children not eligible for antiretroviral therapy
    Edwin D Charlebois
    School of Medicine, University of California, San Francisco, CA 94105, USA
    J Acquir Immune Defic Syndr 55:330-5. 2010
    ..Increasing numbers of HIV-infected children not yet eligible for antiretroviral therapy (ART) are entering health care in Africa. We sought to characterize the risk of short-term disease progression in this population...
  15. ncbi Complications of HIV disease and antiretroviral treatment
    Anne F Luetkemeyer
    University of California San Francisco, San Francisco, CA, USA
    Top HIV Med 18:57-65. 2010
    ..This year's conference also highlighted important data on prevention and optimal treatment of common coinfections that occur in HIV-infected individuals, including tuberculosis, influenza, and viral hepatitis...
  16. ncbi Effect of raltegravir-containing intensification on HIV burden and T-cell activation in multiple gut sites of HIV-positive adults on suppressive antiretroviral therapy
    Steven A Yukl
    San Francisco VA Medical Center SFVAMC and University of California, San Francisco UCSF, San Francisco, California, USA
    AIDS 24:2451-60. 2010
    ..To determine whether raltegravir-containing antiretroviral therapy (ART) intensification reduces HIV levels in the gut...
  17. ncbi Early virological response of zidovudine/lamivudine/abacavir for patients co-infected with HIV and tuberculosis in Uganda
    Padmini Srikantiah
    HIV AIDS Division, San Francisco General Hospital, University of California, San Francisco, California, USA
    AIDS 21:1972-4. 2007
    ..No cases of hypersensitivity or immune reconstitution syndrome were observed. These data support the continuing evaluation of nucleoside-based antiretroviral regimens as an alternative treatment for this population...
  18. ncbi The Effect of a "Universal Antiretroviral Therapy" Recommendation on HIV RNA Levels Among HIV-Infected Patients Entering Care With a CD4 Count Greater Than 500/μL in a Public Health Setting
    Elvin H Geng
    Division of HIV AIDS at San Francisco General Hospital, Department of Medicine, University of California, San Francisco Centers for AIDS Research, Network of Integrated Clinical Systems, San Francisco, California
    Clin Infect Dis 55:1690-7. 2012
    ....
  19. ncbi Tuberculosis drug development: ensuring people living with HIV are not left behind
    Anne F Luetkemeyer
    HIV AIDS Division, San Francisco General Hospital, University of California, San Francisco, CA 94110, USA
    Am J Respir Crit Care Med 184:1107-13. 2011
    ....
  20. ncbi Effect of treatment, during primary infection, on establishment and clearance of cellular reservoirs of HIV-1
    Matthew C Strain
    Department of Physics, University of California at San Diego, La Jolla, California, USA
    J Infect Dis 191:1410-8. 2005
    ..1 IUPM; P<.0005). These results suggest that treatment <6 months after seroconversion may facilitate long-term control of cellular reservoirs that maintain HIV-1 infection during treatment...
  21. ncbi Early virologic failure and the development of antiretroviral drug resistance mutations in HIV-infected Ugandan children
    Theodore D Ruel
    Department of Pediatrics, School of Medicine, University of California, San Francisco, San Francisco, CA 94143 0136, USA
    J Acquir Immune Defic Syndr 56:44-50. 2011
    ..We sought to determine the prevalence of early virologic failure (EVF), to characterize the evolution of ARV-resistance mutations and to predict the impact on second-line therapy...
  22. ncbi Responding to organ failure in HIV-infected patients
    Michelle E Roland
    AIDS Division, Positive Health Program, Department of Medicine, San Francisco General Hospital, University of California, San Francisco, USA
    N Engl J Med 348:2279-81. 2003
  23. ncbi Strategic approaches to antiretroviral treatment
    Diane V Havlir
    University of California San Francisco, San Francisco, CA, USA
    Top HIV Med 11:145-9. 2003
    ..This article summarizes a presentation given by Diane V. Havlir, MD, at the March 2003 International AIDS Society-USA course in Los Angeles...
  24. ncbi Polymerase chain reaction of secA1 on sputum or oral wash samples for the diagnosis of pulmonary tuberculosis
    J Lucian Davis
    Department of Medicine, San Francisco General Hospital and University of California, San Francisco, California 94110, USA
    Clin Infect Dis 48:725-32. 2009
    ..Few studies have assessed their performance among patients infected with HIV, and no studies have assessed their performance with oral wash specimens, which may be easier to obtain than sputum samples...
  25. ncbi The effect of AIDS Clinical Trials Group Protocol 5164 on the time from Pneumocystis jirovecii pneumonia diagnosis to antiretroviral initiation in routine clinical practice: a case study of diffusion, dissemination, and implementation
    Elvin H Geng
    Division of HIV AIDS, San Francisco General Hospital, and Department of Medicine, 995 Potrero Avenue, San Francisco, CA 94110, USA
    Clin Infect Dis 53:1008-14. 2011
    ..Subsequently, the San Francisco General Hospital (SFGH) HIV/AIDS Service performed the SFGH 5164 Initiative to disseminate and implement the findings of ACTG 5164...
  26. ncbi Detection of nonnucleoside reverse-transcriptase inhibitor-resistant HIV-1 after discontinuation of virologically suppressive antiretroviral therapy
    C Bradley Hare
    Dept of Medicine, University of California, San Francisco, CA 94110, USA
    Clin Infect Dis 47:421-4. 2008
    ..Mutations remained detectable for at least 48 weeks in some subjects...
  27. ncbi Tuberculosis as part of the natural history of HIV infection in developing countries
    Gabriel Chamie
    HIV AIDS Division, San Francisco General Hospital, University of California, San Francisco, USA
    Clin Infect Dis 50:S245-54. 2010
    ..Investment in this research will improve the lives of persons infected with HIV and contribute to efforts to reduce the global TB burden...
  28. ncbi Nontuberculous mycobacteria in the HIV infected patient
    Denis Jones
    School of Medicine, University of California, Mail Code 8208, 150 W Washington Street, 100, San Diego, CA 92103, USA
    Clin Chest Med 23:665-74. 2002
    ..Clinicians treating HIV-infected patients must remain familiar with the diagnosis and treatment of these diseases and implement prevention strategies when indicated...
  29. ncbi A randomized trial of treatment interruption before optimized antiretroviral therapy for persons with drug-resistant HIV: 48-week virologic results of ACTG A5086
    Constance A Benson
    University of California, San Diego School of Medicine, San Diego, CA 92103, USA
    J Infect Dis 194:1309-18. 2006
    ..The role of structured treatment interruption (STI) before optimized antiretroviral therapy (ART) in patients with drug-resistant human immunodeficiency virus type 1 (HIV-1) is uncertain...
  30. ncbi Intensive care of patients with HIV infection
    Laurence Huang
    HIV/AIDS Division, San Francisco General Hospital, University of California San Francisco, San Francisco, USA
    N Engl J Med 355:173-81. 2006
  31. ncbi Antimalarial activity of human immunodeficiency virus type 1 protease inhibitors
    Sunil Parikh
    Department of Medicine, San Francisco General Hospital, University of California, San Francisco, Box 0811, San Francisco, California 94110, USA
    Antimicrob Agents Chemother 49:2983-5. 2005
    ..Lopinavir also inhibited the P. falciparum aspartic protease plasmepsin II at a similar concentration (IC50, 2.7 microM). These findings suggest that use of HIV-1 protease inhibitors may offer clinically relevant antimalarial activity...
  32. ncbi Leveraging rapid community-based HIV testing campaigns for non-communicable diseases in rural Uganda
    Gabriel Chamie
    HIV AIDS Division, Department of Medicine, San Francisco General Hospital, University of California San Francisco, San Francisco, California, USA
    PLoS ONE 7:e43400. 2012
    ..We tested the feasibility and diagnostic yield of integrating NCD and communicable diseases into a rapid HIV testing and referral campaign for all residents of a rural Ugandan parish...
  33. ncbi Novel application of Locked Nucleic Acid chemistry for a Taqman assay for measuring diverse human immunodeficiency virus type 1 subtypes
    Peilin Li
    University of California, San Francisco UCSF, Department of Medicine, San Francisco, CA 94121, USA
    J Virol Methods 170:115-20. 2010
    ..765, p<0.0001). This approach to Taqman probe design should be explored further for use in diagnosis and monitoring of HIV in resource-limited settings, especially where several subtypes co-circulate...
  34. ncbi Complications of HIV infection and antiretroviral therapy
    Diane V Havlir
    University of California San Francisco, San Francisco, CA, USA
    Top HIV Med 11:86-91. 2003
  35. ncbi Complications of HIV disease and antiretroviral therapy
    Anne F Luetkemeyer
    University of California San Francisco, San Francisco, CA, USA
    Top Antivir Med 19:58-68. 2011
    ....
  36. ncbi Sudden cardiac death in patients with human immunodeficiency virus infection
    Zian H Tseng
    Section of Cardiac Electrophysiology, Division of Cardiology, University of California San Francisco, San Francisco, CA 94313, USA
    J Am Coll Cardiol 59:1891-6. 2012
    ..The aim of this study was to determine the incidence and clinical characteristics of sudden cardiac death (SCD) in patients with human immunodeficiency virus (HIV) infection...
  37. ncbi Complications of HIV disease and antiretroviral therapy
    Anne F Luetkemeyer
    University of California San Francisco, USA
    Top Antivir Med 20:48-60. 2012
    ....
  38. ncbi The effect of expanded antiretroviral treatment strategies on the HIV epidemic among men who have sex with men in San Francisco
    Edwin D Charlebois
    HIV AIDS Division, Department of Medicine, San Francisco General Hospital, California, USA
    Clin Infect Dis 52:1046-9. 2011
    ..Addition of annual HIV testing for men who have sex with men to universal treatment decreases new infections by 76%...
  39. ncbi Comparison of an interferon-gamma release assay with tuberculin skin testing in HIV-infected individuals
    Annie F Luetkemeyer
    HIV AIDS Division, San Francisco General Hospital, University of California at San Fracisco, San Francisco, Box 0874, Building 80, 995 Potrero Avenue, San Francisco, CA 94110, USA
    Am J Respir Crit Care Med 175:737-42. 2007
    ..Although interferon (IFN)-gamma release assays are approved for the diagnosis of latent tuberculosis infection (LTBI), limited data exist regarding their performance in HIV infection...
  40. ncbi Structured intermittent treatment for HIV disease: Necessary concession or premature compromise?
    Diane V Havlir
    Division of Infectious Diseases, University of California, 150 West Washington Street, Suite 100, San Diego, CA 92103, USA
    Proc Natl Acad Sci U S A 99:4-6. 2002
  41. ncbi Atazanavir: new option for treatment of HIV infection
    Diane V Havlir
    San Francisco General Hospital, University of California, San Francisco, California, USA
    Clin Infect Dis 38:1599-604. 2004
    ..Similar to other protease inhibitors, careful attention must be paid to drug interactions when administering atazanavir with concomitant medications...
  42. ncbi Patents versus patients? Antiretroviral therapy in India
    Diane V Havlir
    University of California, San Francisco, USA
    N Engl J Med 353:749-51. 2005
  43. ncbi Complications of HIV disease and antiretroviral therapy. Highlights of the 11th Conference on Retroviruses and Opportunistic Infections, February 8-11, 2004, San Francisco, California, USA
    Judith S Currier
    University of California Los Angeles, Los Angeles, CA, USA
    Top HIV Med 12:31-45. 2004
    ..This article summarizes these presentations...
  44. ncbi Persistent HIV-1-specific cellular responses despite prolonged therapeutic viral suppression
    Victor Appay
    Medical Research Council Human Immunology Unit, Institute of Molecular Medicine, John Radcliffe Hospital, Oxford, UK
    AIDS 16:161-70. 2002
    ..It leads to significant reductions of plasma viremia, often to undetectable levels, but it can also be linked with the reduction and disappearance of detectable HIV-specific CD8 T-cell responses...
  45. ncbi Baseline predictors of CD4 T-lymphocyte recovery with combination antiretroviral therapy
    Kara K Bennett
    SDAC, Harvard School of Public Health, Boston, Massachusetts 02115, USA
    J Acquir Immune Defic Syndr 31:20-6. 2002
    ..01) had higher increases in phase I changes. Phase II CD4 cell counts did not depend solely on baseline HIV-1 RNA levels and CD4 cell counts but on their interaction (p =.0001) as well as on achieving virologic suppression (p =.0009)...
  46. ncbi High-dose lopinavir/ritonavir in highly treatment-experienced HIV-1 patients: efficacy, safety, and predictors of response
    Daniel Podzamczer
    Infectious Disease Service, Hospital Universitari de Bellvitge, Barcelona, Spain
    HIV Clin Trials 8:193-204. 2007
    ..To investigate the efficacy and safety of high-dose lopinavir/ritonavir (LPV/r) therapy in multiple protease inhibitor, non-nucleoside reverse transcriptase inhibitor (NNRTI)-experienced subjects...
  47. ncbi Rapid increase in tuberculosis incidence soon after infection with HIV--a new twist in the twin epidemics
    Padmini Srikantiah
    J Infect Dis 191:147-9. 2005
  48. ncbi Complications of HIV disease and antiretroviral therapy
    Judith S Currier
    University of California Los Angeles, Los Angeles, CA, USA
    Top HIV Med 13:16-23. 2005
    ....
  49. ncbi Antiretroviral therapy and TB
    Soumya Swaminathan
    Division of HIV/AIDS, Tuberculosis Research Centre, Chennai, India
    Trop Doct 36:73-9. 2006
    ..Despite the complexities presented by co-infection, many programmes have integrated care and are successfully treating patients with both HIV and TB...
  50. ncbi HIV RNA suppression among HIV-infected Ugandan children with measles
    Theodore D Ruel
    J Acquir Immune Defic Syndr 48:225-7. 2008
  51. ncbi Complications of HIV disease and antiretroviral therapy
    Diane V Havlir
    University of California San Francisco, CA, USA
    Top HIV Med 14:27-35. 2006
    ..This review will summarize information on complications of antiretroviral therapy in resource-limited settings, hepatitis C virus, tuberculosis, and discussion of metabolic, cardiovascular, and renal complications...
  52. ncbi Treatment strategies for HIV-infected patients with tuberculosis: ongoing and planned clinical trials
    Francois Xavier Blanc
    Agence Nationale de Recherches sur le Sida et les Hepatites Virales, Paris, France
    J Infect Dis 196:S46-51. 2007
    ..Here, we present an overview of these ongoing or planned clinical studies, which are supported by international agencies...
  53. ncbi Interruption of antiretroviral treatment in HIV-infected patients with preserved immune function is associated with a low rate of clinical progression: a prospective study by AIDS Clinical Trials Group 5170
    Daniel J Skiest
    Baystate Medical Center, Springfield, MA 01106, USA
    J Infect Dis 195:1426-36. 2007
    ..We sought to determine the safety of treatment interruption (TI) and to identify parameters that would define patients with human immunodeficiency virus (HIV) for whom TI is safer...
  54. ncbi Complications of HIV disease and therapy
    Judith S Currier
    University of California Los Angeles, Los Angeles, CA, USA
    Top HIV Med 15:40-7. 2007
    ..As the field of clinical research in HIV continues to mature, we are repeatedly surprised by the findings from well-designed studies...
  55. ncbi Memory CD8+ T cells vary in differentiation phenotype in different persistent virus infections
    Victor Appay
    MRC Human Immunology Unit, Institute of Molecular Medicine, John Radcliffe Hospital, Oxford, UK
    Nat Med 8:379-85. 2002
    ..These findings challenge the current definitions of memory and effector subsets in humans, and suggest that ascribing effector and memory functions to subsets with different differentiation phenotypes is no longer appropriate...
  56. ncbi The case for earlier treatment of HIV infection
    Scott D Holmberg
    Division of HIV AIDS Prevention, Centers for Disease Control and Prevention, Atlanta, GA 30333, USA
    Clin Infect Dis 39:1699-704. 2004
    ..Given these accumulating data, we believe reconsideration of the "when-to-start" question is timely and justified...